Automatic generic-drug substitution poses several big problems, says NYU Professor Melissa Schilling.» Read More
Too few influential doctors are telling the public if they have financial ties to the companies that make lifesaving drug-coated stents.
Time to face the foul facts, America. To profit amid our economic pain you may have no choice but to dive headlong into the muck.
Here's the opening line of a press release sent my way: "Have you ever wondered what the world is like for a person with schizophrenia?" Um, no. I haven't. I mean, I have enough on my mind already.
On St. Patrick's Day (March 17), Bernie McGinn saw a lot of green for Ford: he told CNBC the automaker was a "buy." Since then, the troubled carmaker's shares are up 65.2 percent. Where's the head of McGinn Investment Management going now?
Burlington Northern, the railroad in which Warren Buffet owns at 20% stake, reported its highest profits ever on Tuesday. Is trading in Buffet’s wake your ticket to ride?
Wall Street’s on the edge of its seat ahead of Wednesday’s interest-rate announcement. You should be on the phone with your broker.
It's a big day for pipeline progress...or not. Late Friday, Merck and Schering-Plough announced that the Food and Drug Administration won't approve their combo Claritin-Singulair combo pill for allergies.
Wyeth Tuesday said its first-quarter net profit fell slightly, hurt by the sudden launch early this year of a generic form of its Protonix ulcer drug, but surprisingly strong sales enabled the company to beat Wall Street profit forecasts.
The Dow pulled back Monday after a weaker-than-expected profit report from Bank of America stirred concerns about the health of corporate earnings. What's the "Word on The Street?"
Intel shares gapped higher after hours on guidance, setting up for a higher market open Tuesday. Also, a breakdown of the oil trade, CSX earnings and more.
All three major indexes finished slightly higher Tuesday, led by energy and bank stocks, as investors processed some not-horrible earnings results. Airline stocks skidded amid concerns about fuel prices and viability.
Johnson & Johnson posted better-than-expected first-quarter earnings on Tuesday, sending its shares higher, as aggressive cost cutting helped offset plunging sales of anemia drugs hit by safety concerns and medicines facing generic competition.
Dow component and healthcare conglomerate (drugs, consumer products, medical devices) Johnson & Johnson beat and boosted. That's Wall Street jargon for earnings coming in higher than expectations and the guidance for the rest of the year being raised. So, why did the stock go down?
Stocks traded mixed Tuesday as not-horrible earnings failed to quell market jitters about earnings.
Stocks opened higher Tuesday after a tame core inflation reading, a better-than-expected manufacturing report and news of a Delta-Northwest deal.
Futures actually moved up at 8:30 ET, despite PPI much stronger than anticipated (core PPI was in-line, apparently because car and truck prices were dropping; the NY Empire State Index was stronger than expected).
In Monday’s Web Extra the traders reveal how to play Johnson & Johnson, CSX Corp. as well as a second airline merger.
Can we please get some upside earnings reports this quarter? No financial exposure here. Instead, this Dow Industrial has plenty of overseas business to be helped by the weaker dollar and guardedly optimistic expectations for key business segments.
To give investors an edge, CNBC asked market experts to share their best retail plays.
Find out if these viewers are investing according to Mad Money's most important rule.